These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38078606)

  • 1. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
    Capeau J; Lagathu C; Béréziat V
    Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
    Perna A; Carleo MA; Mascolo S; Guida A; Contieri M; Sellitto C; Hay E; De Blasiis P; Lucariello A; Guerra G; Baldi A; De Luca A; Maggi P; Esposito V
    AIDS; 2023 Mar; 37(4):561-570. PubMed ID: 36504092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
    Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
    Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
    AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and adipose tissue: A long history linked to therapeutic classes of antiretrovirals.
    Capeau J; Lagathu C; Ngono Ayissi K; Fève B; Béréziat V
    Ann Endocrinol (Paris); 2024 Jun; 85(3):255-258. PubMed ID: 38871510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes.
    McCann K; Shah S; Hindley L; Hill A; Qavi A; Simmons B; Serenata C; Sokhela S; Venter WDF
    AIDS; 2021 Aug; 35(10):1657-1665. PubMed ID: 33927086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
    Lake JE; Trevillyan J
    Curr Opin HIV AIDS; 2021 May; 16(3):148-151. PubMed ID: 33797433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.
    Chen GJ; Sun HY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Lin KY; Liu WC; Su YC; Hung CC
    J Microbiol Immunol Infect; 2023 Oct; 56(5):988-995. PubMed ID: 37574435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
    N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
    Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
    Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Adverse Effects of HIV Integrase Inhibitors.
    Kolakowska A; Maresca AF; Collins IJ; Cailhol J
    Curr Treat Options Infect Dis; 2019; 11(4):372-387. PubMed ID: 33380904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.
    Verburgh ML; Wit FWNM; Boyd A; Reiss P; Van der Valk M;
    AIDS; 2023 Oct; 37(12):1843-1850. PubMed ID: 37433218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biktarvy for the treatment of HIV infection: Progress and prospects.
    De Clercq E; Zhang Z; Huang J; Zhang M; Li G
    Biochem Pharmacol; 2023 Nov; 217():115862. PubMed ID: 37858869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.
    Verburgh ML; Wit FWNM; Boyd A; Verboeket SO; Reiss P; van der Valk M
    Open Forum Infect Dis; 2022 Jul; 9(7):ofac291. PubMed ID: 35873291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.